Press Releases

Filter Releases

Date	Title and Summary	View
Toggle SummaryJun 01, 2013	Onconova Announces Presentation of Favorable Safety and Activity Data from Phase 2 Study of Oral Rigosertib in Lower Risk Myelodysplastic Syndromes Interim Results Presented at 2013 ASCO Annual Meeting Indicate Strong Signal of Transfusion Independence	View HTML Onconova Announces Presentation of Favorable Safety and Activity Data from Phase 2 Study of Oral Rigosertib in Lower Risk Myelodysplastic Syndromes 18.5 KB
Toggle SummaryMay 15, 2013	Onconova Announces Presentation of Oral Rigosertib Safety and Activity Data in Lower Risk Myelodysplastic Syndromes at the 2013 ASCO Annual Meeting	View HTML Onconova Announces Presentation of Oral Rigosertib Safety and Activity Data in Lower Risk Myelodysplastic Syndromes at the 2013 ASCO Annual Meeting 14.3 KB
Toggle SummaryMay 09, 2013	Onconova Completes Enrollment in ONTIME Pivotal Phase 3 Study of Rigosertib in Patients with High-risk Myelodysplastic Syndromes	View HTML Onconova Completes Enrollment in ONTIME Pivotal Phase 3 Study of Rigosertib in Patients with High-risk Myelodysplastic Syndromes 15.4 KB
Toggle SummaryApr 09, 2013	Onconova Announces Presentation of Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer at AACR 2013 Annual Meeting Oral Rigosertib Progresses to Phase 2 Clinical Trial in Squamous Cell Head and Neck Cancers	View HTML Onconova Announces Presentation of Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer at AACR 2013 Annual Meeting 17 KB
Toggle SummaryApr 02, 2013	Onconova Appoints Ajay Bansal as Chief Financial Officer	View HTML Onconova Appoints Ajay Bansal as Chief Financial Officer 14.5 KB
Toggle SummaryJan 09, 2013	GVK Biosciences and Onconova Therapeutics Establish Novel Joint Development Partnership to Advance New Drugs for Cancer	View HTML GVK Biosciences and Onconova Therapeutics Establish Novel Joint Development Partnership to Advance New Drugs for Cancer 14.8 KB
Toggle SummaryDec 10, 2012	Onconova Presents Positive Clinical Results for Rigosertib at ASH Meeting Three Trials Demonstrate Safety and Tolerability in Hematological Malignancies	View HTML Onconova Presents Positive Clinical Results for Rigosertib at ASH Meeting 17.3 KB
Toggle SummaryOct 09, 2012	Onconova Appoints Dr. Thomas J. McKearn as President, Research and Development	View HTML Onconova Appoints Dr. Thomas J. McKearn as President, Research and Development 13.5 KB
Toggle SummaryOct 03, 2012	Onconova Presents Positive Clinical Trial Results for Radiation Injury Protector Ex-RAD®	View HTML Onconova Presents Positive Clinical Trial Results for Radiation Injury Protector Ex-RAD® 16.8 KB
Toggle SummarySep 19, 2012	Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib Rigosertib in Late-Stage Studies for MDS and Pancreatic Cancer	View HTML Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib 17.6 KB
Toggle SummaryJun 01, 2012	Onconova Presents Clinical Trial Data for Oral Rigosertib at ASCO Annual Meeting Two Clinical Trials Assessed Oral Safety and Bioavailability	View HTML Onconova Presents Clinical Trial Data for Oral Rigosertib at ASCO Annual Meeting 22.2 KB
Toggle SummaryMay 10, 2012	Onconova Advances Oral Rigosertib to Phase II Clinical Trial in Myelodysplastic Syndromes Complete Phase I Data to be Reported at ASCO 2012 Annual Meeting	View HTML Onconova Advances Oral Rigosertib to Phase II Clinical Trial in Myelodysplastic Syndromes 18.6 KB